Who is sponsoring NCT04077255?

NCT04077255 is sponsored by National Cancer Center, Korea.

What drugs are being tested in NCT04077255?

Interventions in NCT04077255: Anti-EGFR antibody in combination with weekly paclitaxel.

What condition does NCT04077255 study?

NCT04077255 studies Adenocarcinoma of the Stomach.

Is NCT04077255 still recruiting?

NCT04077255 is currently status unknown. Last updated 30 November 2022.

Last reviewed 2022-11-30 · How we verify

NCT04077255

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EGFR-targeted Therapy for Gastric Cancer

Status unknown Phase 2 Last updated 30 November 2022

What this trial tests

Phase 2 trial testing Anti-EGFR antibody in combination with weekly paclitaxel in Adenocarcinoma of the Stomach in 19 participants. Status unknown.

Timeline

1 September 2019

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	National Cancer Center, Korea
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	19
Start date	1 September 2019
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	1 location across South Korea

Drugs / interventions tested

Anti-EGFR antibody in combination with weekly paclitaxel — full drug profile →

Conditions studied

Adenocarcinoma of the Stomach — all drugs for Adenocarcinoma of the Stomach →

Sponsor

National Cancer Center, Korea

Who can join

18 and older, any sex, with Adenocarcinoma of the Stomach. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Based on targeted NGS panel results, metastatic gastric cancer patients with gene amplifications will receive either anti-EGFR antibody (GC-1118) in combination with weekly paclitaxel as a second-line therapy.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention.
De Luca A, Esposito Abate R, Rachiglio AM, Maiello MR, et al · · 2020 · cited 87× · PMID 32962091 · DOI 10.3390/ijms21186856
Tyrosine Kinase Receptors in Oncology.
Esteban-Villarrubia J, Soto-Castillo JJ, Pozas J, San Román-Gil M, et al · · 2020 · cited 72× · PMID 33198314 · DOI 10.3390/ijms21228529
FGFR4: A promising therapeutic target for breast cancer and other solid tumors.
Levine KM, Ding K, Chen L, Oesterreich S. · · 2020 · cited 68× · PMID 32492514 · DOI 10.1016/j.pharmthera.2020.107590
Targeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives.
Luo D, Liu Y, Lu Z, Huang L. · · 2025 · cited 31× · PMID 39923010 · DOI 10.1186/s10020-025-01075-y
Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer.
Adashek JJ, Arroyo-Martinez Y, Menta AK, Kurzrock R, et al · · 2020 · cited 19× · PMID 32850413 · DOI 10.3389/fonc.2020.01312
Identification of Potential Genomic Alterations Using Pan-Cancer Cell-Free DNA Next-Generation Sequencing in Patients With Gastric Cancer.
Kim B, Kim Y, Cho JY, Lee KA. · · 2024 · cited 6× · PMID 37903652 · DOI 10.3343/alm.2023.0187

Verify or expand the search:

Other recruiting trials for Adenocarcinoma of the Stomach

Currently open trials in the same condition.

NCT05872685 — Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS- · Phase 2 · recruiting
NCT05729646 — Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma · Phase 2 · recruiting
NCT05715931 — Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastri · Phase 2 · recruiting
NCT06121700 — Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer · Phase 2 · recruiting
NCT04878783 — Radiomics and Molecular Expression Predictive Model for Esophago-Gastric Junction and Gastric Cancer TRG · active not recruiting

Other National Cancer Center, Korea trials

Trials by the same sponsor.

NCT07399561 — Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy · NA · not yet recruiting
NCT07121478 — Patients With High-grade Pancreatic Neuroendocrine Tumors · Phase 2 · enrolling by invitation
NCT07171528 — Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer · Phase 2 · recruiting
NCT07125924 — Intravesical Hyaluronic Acid (HA) for Preventing Radiation Cystitis on Bladder Cancer · NA · not yet recruiting
NCT07041515 — Knowledge-enhanced Digital Intervention to Prevent Low Anterior Resection Syndrome · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04077255 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Center, Korea
Last refreshed: 30 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04077255.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing